Clinical trial
A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07903636 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started December 2026. Interventional study, Phase 2, 55 participants (estimated). Lead sponsor Institute of Hematology & Blood Diseases Hospital, China; China. Primary measure: Overall Response Rate (ORR).
How it compares
1,104 similar trials: same condition (Multiple Myeloma) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-Arm, Phase II Clinical Trial of QLS4131 for the Treatment of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- December 1, 2028
- Enrollment
- 55 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: multiple myeloma (mm)
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| QLS4131 | Experimental | QLS4131 |
Show registry wordingParticipants will receive QLS4131 12 mg by subcutaneous injection. Step-up doses of 0.6 mg and 3 mg will be administered before the first full dose. QLS4131 will be given every 2 weeks during Cycle 1 and every 4 weeks thereafter. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, investigator decision, or completion of 24 cycles. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Overall Response Rate (ORR) | From the first dose to the end of Cycle 24 (each cycle is 28 days). |
Lead sponsor's other trials
Institute of Hematology & Blood Diseases Hospital, China, most recent start first.
+407 more trials See the organization page
Similar trials
Same condition (Multiple Myeloma) and phase, most recent start first.
+1,099 more trials See the condition page